Remternetug
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Remternetug
- Immunoglobulin G1 [de-452-lysine], anti-(human [3-pyroglutamyl] β-amyloid) (human monoclonal LY3372993 γ1-chain), disulfide with human monoclonal LY3372993 κ-chain, dimer
- immunoglobulin g1 de 452 lysine anti human 3 pyroglutamyl β amyloid human monoclonal ly3372993 γ1 chain disulfide with human monoclonal ly3372993 κ chain dimer
- ly 3372993
- LY-3372993
- ly3372993
- LY3372993
- remternetug
- Remternetug
- Remternetug (Reference)
- Remternetug (Test)
- remternetug [INN]
- REMTERNETUG [USAN]
- remternetug inn
- remternetug usan
- CAS registry numbers
- 2571940-41-3
- ChEMBL ID
- CHEMBL5095484
- FDA ingredient codes (UNII)
- A5HTA4J6ME
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- Alzheimer Disease
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
Open Targets indications
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 3
- NCT03720548
- NCT04451408
- NCT05463731
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYPMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGGSGSYYNGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSTLSASVGDRVTITCRASQSLGNWLAWYQQKPGKAPKLLIYQASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYKGSFWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 302 $ 302''''
- Component
- Glycosylation sites (N)
- Sequence
- 302 $ 302''
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 149-205 $ 149''-205'' $ 214'-225 $ 214'''-225'' $ 231-231'' $ 234-234'' $ 266-326 $ 266''-326'' $ 372-430 $ 372''-430''
Related records
Trials (8)
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)
- A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants
- A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
- A Study of Remternetug (LY3372993) in Healthy Chinese Participants
- A Study of Remternetug (LY3372993) in Healthy Participants
- A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
In development for (1)
- Alzheimer disease Phase 3